Discrimination of Potent Inhibitors of Toxoplasma gondii Enoyl-Acyl Carrier Protein Reductase by a Thermal Shift Assay by Afanador, G.A. et al.
Discrimination of Potent Inhibitors of Toxoplasma gondii Enoyl-
Acyl Carrier Protein Reductase by Thermal Shift Assay
Gustavo A. Afanador1, Stephen P. Muench2, Martin McPhillie3, Alina Fomovska4, Arne
Schön5, Ying Zhou4, Gang Cheng6, Jozef Stec7, Joel S. Freundlich8, Hong-Ming Shieh9,
John W. Anderson9, David P. Jacobus9, David A. Fidock10, Alan P. Kozikowski6, Colin W.
Fishwick11, David W. Rice3, Ernesto Freire5, Rima McLeod4, and Sean T. Prigge1,*
1Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of
Public Health, Baltimore, MD 21205, USA
2School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK
3Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, UK
4Department of Ophthalmology and Visual Sciences, Pediatrics (Infectious Diseases),
Committees on Genetics, Immunology, and Molecular Medicine, Institute of Genomics and
Systems Biology, and The College, The University of Chicago, Chicago, IL 60612, USA
5Department of Biology, The Johns Hopkins University, Baltimore, MD 21218, USA
6Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of
Illinois at Chicago, Chicago, IL 60612, United States
7Chicago State University, College of Pharmacy, DH 203-3, 9501 South King Drive, Chicago,
Illinois 60628, United States
8Departments of Pharmacology & Physiology and Medicine, Center for Emerging and
Reemerging Pathogens, UMDNJ – New Jersey Medical School, 185 South Orange Avenue
Newark, NJ 07103, USA
9Department of Medicinal Chemistry, Jacobus Pharmaceutical Company, Princeton, NJ 08540,
USA
10Department of Microbiology & Immunology and Division of Infectious Diseases, Department of
Medicine, Columbia University Medical Center, New York, NY 10032, USA
11School of Chemistry, University of Leeds, Leeds, LS2 9JT, UK
Abstract
Many microbial pathogens rely on a type II fatty acid synthesis (FASII) pathway which is distinct
from the type I pathway found in humans. Enoyl-Acyl Carrier Protein Reductase (ENR) is an
essential FASII pathway enzyme and the target of a number of antimicrobial drug discovery
efforts. The biocide triclosan is established as a potent inhibitor of ENR and has been the starting
point for medicinal chemistry studies. We evaluated a series of triclosan analogs for their ability to
inhibit the growth of Toxoplasma gondii, a pervasive human pathogen, and its ENR enzyme
(TgENR). Several compounds were identified that inhibited TgENR at low nanomolar
concentrations, but could not be further differentiated due to the limited dynamic range of the
TgENR activity assay. Thus, we adapted a thermal shift assay (TSA) to directly measure the
dissociation constant (Kd) of the most potent inhibitors identified in this study as well as inhibitors
from previous studies. Furthermore, the TSA allowed us to determine the mode of action of these
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compounds in the presence of NADH or NAD+ cofactors. We found that all of the inhibitors bind
to a TgENR/NAD+ complex, but that they differed in their dependence on NAD+ concentration.
Ultimately, we were able to identify compounds which bind to the TgENR/NAD+ complex in the
low femtomolar range. This shows how TSA data combined with enzyme inhibition, parasite
growth inhibition data and ADMET predictions allow for better discrimination between potent
ENR inhibitors for future medicine development.
INTRODUCTION
Toxoplasma gondii is an obligate intracellular, protozoan parasite that infects about one third
of the world’s population, causing substantial morbidity and mortality.1–6 The life cycle of
T. gondii is comprised of a sexual phase that only takes place in the primary host (cats of the
Felidae family), and an asexual phase that can occur in any warm-blooded animal, including
humans.7–8 Currently there is no available vaccine to prevent infection in humans, and only
the antifolate medicines sulfadiazine and pyrimethamine are typically used for treatment of
T. gondii in humans.2, 9 Sulfonamides are associated with hypersensitivity, and
pyrimethamine with bone marrow toxicity. Even though these medications are effective
against tachyzoites, the obligate intracellular form of the parasite in the acute stage of the
disease, they are ineffective against the encysted, latent bradyzoites. There is no available
treatment to eliminate bradyzoites in humans.10 T. gondii infection in immunocompetent
individuals is generally asymptomatic and self-limiting, whereas in immunocompromised
people, T. gondii infection can cause eye and brain disease such as toxoplasmic encephalitis,
chorioretinitis and in severe cases can be fatal.11–12 Pregnant women are especially at risk
because the parasite can be transmitted from mother to fetus, and can lead to congenital
toxoplasmosis that may result in abortion, neonatal death, or fetal abnormalities.2, 9, 13–18
T. gondii parasites contain a plastid organelle, called the apicoplast, which harbors plant-like
metabolic pathways.19 One pathway that resides in the apicoplast is the machinery for a type
II fatty acid synthesis (FASII) pathway which is prokaryotic-like.20–21 The FASII pathway
in T. gondii has been shown to be essential for parasite survival making it an attractive target
for drug discovery efforts.22–26 In malaria parasites, a similar FASII pathway is critical for
liver stage development27–28 and is thought to have an important role in the synthesis of
lipoic acid.29 In contrast to the type II pathway, humans rely on a distinct type I pathway for
bulk fatty acid synthesis, which is encoded in a single polypeptide chain.30 Fatty acid
biosynthesis is an iterative process involving the condensation of malonyl-CoA with a
nascent fatty acid chain that is covalently bound to Acyl Carrier Protein (ACP). The enzyme
Enoyl-ACP Reductase (ENR) is responsible for the final reductive step in each round of
fatty acid chain elongation, the NADH-dependent reduction of trans-2-enoyl-ACP to acyl-
ACP.31 Many inhibitors of bacterial and parasitic ENR enzymes have been previously
described including diazaborines, isoniazid and triclosan.32–34 It has been shown that
triclosan inhibits TgENR with an IC50 value of less than 20 nM in an in vitro inhibition
assay using pure recombinant TgENR.35 Triclosan also inhibits growth of T. gondii parasites
with an IC50 of about 200 nM, presumably due to its inhibition of the FASII pathway.23
Even though triclosan is a potent inhibitor of TgENR, it has limitations including poor
bioavailability and impairment of muscle contractility that prevent it from being a safe and
effective medicine.36 Instead, triclosan has been exploited as a scaffold to generate a series
of analogues, many of which are also potent inhibitors of TgENR.35, 37–39 In this study, we
report the inhibitory properties of a set of 2'-, 4'-, 5- and 6-substituted triclosan analogues
developed as inhibitors of Plasmodium falciparum ENR (PfENR) and Mycobacterium
tuberculosis ENR (MtInhA).27, 40–43 Several of these compounds inhibited TgENR at low
nanomolar concentrations, the lowest concentrations that we are able to assess in our
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enzymatic activity assay. To further characterize the inhibitory properties of these
compounds and potent inhibitors from previous medicinal chemistry efforts37–38 we
employed a thermal shift assay (TSA). Using this assay, we were able to confirm the mode
of action for all of the compounds as binding to the TgENR/NAD+ complex rather than to
the TgENR/NADH complex or to TgENR alone. Combined with thermodynamic parameters
determined by differential scanning calorimetry, we calculated dissociation constants44–46
for NAD+ and NADH binding to TgENR as well as for inhibitor binding to the TgENR/
NAD+ complex. The Kd values we determined range from 6 mM (for NAD+ binding to
TgENR) to 6.3 fM (for compound 19 binding to the TgENR/NAD+ complex), highlighting
the large dynamic range of the TSA. Consequently, TSA results combined with enzyme and
parasite inhibition data provide a better basis to differentiate between potent ENR inhibitors.
MATERIALS AND METHODS
Compound Preparation and Synthesis
Compounds were designed and synthesized as described by Alan Kozikowski 37–38 and
Jacobus Pharmaceutical Inc.27, 40–43 The purity of compounds 1–4,43 5–10,40 11–14,41–42
15–18,27 19–29,38 and 30–3237 was >95% as determined by HPLC and the identity of each
compound was verified by high resolution mass spectrometry. The compounds were initially
dissolved in DMSO at a concentration of 10 mM, and further diluted to required
concentrations in culture media (described below). For cell proliferation assays the final
concentration of DMSO was not more than 0.1%, whereas for the in vitro TgENR enzyme
assay the DMSO concentration was 1%.
Parasite and Cell Culture
The strain of T. gondii parasites used in this set of experiments was a modified type I RH
strain which expresses yellow florescent protein (RH-YFP), kindly provided by Dr. Boris
Striepen (University of Georgia). Parasites were maintained in confluent monolayers of
Human Foreskin Fibroblast (HFF) cells at 37 °C and 5% CO2 in culture medium consisting
of Iscove’s Modified Dulbecco’s Medium supplemented with 10% Fetal Calf Serum, 1%
Glutamax, and 1% Penicillin-Streptomycin-Fungizone (Invitrogen).
In vitro Challenge Assay
Growth inhibition of T. gondii was assessed as previously described.38 Host cells containing
RH-YFP parasites were lysed by double passage through a 25g needle, and separated from
the parasites by filtration and centrifugation. Confluent monolayers of HFF cells in 96-well
plates (Falcon 96 Optilux Flat-bottom) were infected with 3,500 parasites per well. Parasites
were allowed to infect host cells for one hour, after which experimental compounds and
control solutions were added. Seventy-two hours later, the parasite burden was assessed by
measuring relative fluorescence using a Synergy H4 Hybrid Reader (BioTek) and Gen5 1.10
software. All compounds and control solutions were tested in triplicate exemplars.
Biological replicates of each experiment were performed twice for compound 17 and three
times for all other compounds. The compounds were tested in a dilution series from 10 µM
to 0.01 µM concentrations as described previously.38 In each assay, these results were
compared with those for DMSO control and triclosan. Other internal controls included a
curve obtained with varying concentrations of parasites to confirm that each assay detected
differing numbers of parasites, and cultures treated with a known inhibitory concentration of
pyrimethamine and sulfadiazine as a positive control. Inhibitory index was calculated as:
[RFU(compound)−RFU(control fibroblasts)]/[RFU(DMSO control)−RFU(control fibroblasts)]×100.
MIC50 is defined as the compound concentration required to inhibit replication by 50%.
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Human cell proliferation assay
Potential cytotoxic effects of the compounds were assessed using Cell Proliferation Reagent
WST-1 (Roche), which measures the metabolic activity of viable cells. Confluent HFF cells
in 96-well plates were treated under the same conditions as in the challenge assay described
above, except that the cells were not infected with parasites. After 72 hours, the cells were
incubated with WST-1 reagent for 1–2 hrs, and cell viability was assessed by measuring the
absorbance at 420 nm of the final colored product, which correlates directly with cell
number. All samples were tested in triplicate in at least two biological replicates.
Inhibition of TgENR activity in vitro and enzymatic assay
Recombinant TgENR was purified as described previously.47 A 96-well plate assay was
used to measure the inhibition of TgENR as described previously.37–38 Briefly, a
SpectraMax M2 plate reader was used to monitor the activity of TgENR by consumption of
NADH (ε340 = 6220 M−1cm−1). Reactions were carried out in a final volume of 100 µL in
96 well Corning UV plates. A reaction mixture was used containing 100 µM crotonyl-CoA
(Sigma), 1 µL of DMSO (or compounds dissolved in DMSO), 5nM TgENR, 100 mM Na/K
Phosphate pH 7.5 150 mM NaCl and 100 µM NADH. The enzymatic activity was
determined by comparing the slopes of the absorbance curves for each well to those of the
blanks in the first column of the plate. Each compound was measured in duplicate at 1 µM
final concentration. Potent inhibitors (>90% inhibition at 1 µM) were further analyzed to
determine IC50 values in triplicate. Nonlinear regression analysis was performed using
GraphPad Prism software.
To calculate the Km and kcat values for NADH and Crotonyl-CoA we followed a method
described previously.25 The Km and kcat were determined at variable concentrations of
NADH (0–0.5 mM) in triplicate and a fixed concentration of crotonyl-CoA (100 μM). The
Km and kcat for Crotonyl-CoA were determined at concentrations ranging from 0.8–150 µM
and a fixed concentration of NADH (100µM). Kinetic parameters were calculated by fitting
the initial velocity data to the Michaelis–Menten equation using GraphPad Prism software.
Thermal Shift Assay (TSA)
A real-time PCR (RT-PCR) instrument, in the presence of Sypro Orange (an
environmentally sensitive fluorescent dye), was used to monitor the thermal unfolding of
TgENR alone or in the presence of ligands. The TSA was modified from previous
reports44–46 to measure the thermal melting temperature (Tm) of TgENR. Real-time PCR
tube strips (Eppendorf) were used to hold 31 µL mixtures containing final concentrations of
2 µM TgENR, 20 µM inhibitor and 100 µM cofactor. The reactions were set up with a 28 µl
mixture of TgENR and buffer (20 mM HEPES pH 7.5, 100 mM NaCl) to which 1 µL of
water (or cofactor dissolved in water), 1 µL DMSO (or inhibitor dissolved in DMSO), and 1
µL of Sypro Orange (Sigma, Product Number S-5692 at a final concentration of 5X) was
added. The reaction mixture was incubated in the RT-PCR machine (Applied Biosystems,
Step One Plus Real-Time PCR System) for 2 minutes at 20 °C followed by 0.2 °C increases
in the temperature every 10 seconds until a final temperature of 80 °C was reached. During
the thermal scan, fluorescence was monitored using a pre-defined TAMRA filter in which
an increase in Sypro Orange fluorescence was observed upon thermal denaturation of
TgENR. The derivative of the fluorescence curve was used to determine the Tm (as seen in
Figure 1). The initial Tm in the absence of ligands, but in the presence of DMSO, served as
the baseline temperature (To) for determining temperature shifts (ΔTm). All measurements
were made in triplicate.
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Calculation of binding constant (Kd)
The Tm values obtained in the TSA were used to calculate the dissociation constant (Kd) as
described by Mei-Chu Lo and coworkers.44 The dissociation constant at the melting
temperature was calculated using the equation
in which To is the melting temperature of TgENR with no ligands (baseline), Tm is the
melting temperature of TgENR in complex with one or more ligands, R is the gas constant,
ΔH is the enthalpy of protein unfolding, ΔCp is the heat capacity change on protein
unfolding, and [LTm] is the free ligand concentration at Tm. The two thermodynamic
parameters (ΔH and ΔCp) were measured by Differential Scanning Calorimetry. A
temperature scan of 0.33 mg/mL TgENR from 10 to 65 °C at 1 °C/min was monitored using
a VP-DSC microcalorimeter (MicroCal). The change in heat capacity (ΔCpTo) of 3.8 kcal/K/
mol was estimated from the difference in baselines between the baselines of the denatured
and native states. The enthalpy (ΔHTo) was obtained from the area under the curve yielding
a value of 228.7 kcal/mol. The dissociation constant at the melting temperature was
normalized to temperature T (37 °C) using the equation
which ΔHL(T) is the van’t Hoff enthalpy of binding at temperature T, estimated to be −15
kcal/mol.44, 48
Molecular Docking
Molecular docking studies were performed using AutoDock 4.2,49 SwissPDB Viewer50 and
MacroModel version 8.1 (Schrodinger, LLC, New York, NY, 2012) in conjunction with the
X-ray crystal structures of T. gondii ENR in complex with inhibitors triclosan (PDB ID:
202S)51 and benzimidazole (PDB ID: 1LX6)52 available from the Brookhaven Protein
DataBank. A 10 Å radius of the active site was used to dock the synthesized molecules with
a grid box margin of 62. All other docking parameters were left as default. The obtained
docking poses were analyzed using PyMol.
RESULTS AND DISCUSSION
Parasite inhibition, host cell cytotoxicity, and inhibition of TgENR enzymatic activity
A structure-based approach was adopted by Freundlich and colleagues to develop 2'-, 4'-, 5-
and 6-substituted triclosan analogues against PfENR and MtInhA.27, 40–43 In the present
study, we evaluated 18 of these analogues against Toxoplasma gondii. The triclosan
analogues were first tested for efficacy against T. gondii tachyzoites in vitro. Triclosan was
also included in the assay for a direct comparison. Type 1 RH tachyzoites that express
Yellow Fluorescent Protein (RH-YFP) were used, allowing parasite proliferation to be
assessed by means of a fluorometric assay, since relative fluorescence is directly correlated
with parasite viability. A seventy-two hour end-point was chosen to allow slow acting
compounds to take effect. Seven compounds emerged as the most effective inhibitors of T.
gondii tachyzoites: 5, 8, 9, 10, 15, 16 and 17 (Table 1). These compounds demonstrated an
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efficacy equivalent to triclosan (MIC50 of 2.8 µM), with MIC50 values ranging from 1.6–3.5
µM. The compounds were also tested for cytotoxic activity against Human Foreskin
Fibroblast host cells and exhibited no cytotoxic effects at the highest concentration tested
(10 µM). These results demonstrate that inhibition of parasite growth at lower concentrations
did not result from killing the host cells, however, since we did not reach the MIC50 for
inhibition of host cell proliferation, we do not know the overall selectivity of our
compounds.
The triclosan analogues were also screened in duplicate at 1 µM for inhibition of TgENR in
an in vitro inhibition assay. Those analogues with significant inhibitory activity (>90 % at 1
µM) were subsequently assayed in triplicate to determine their IC50 values (Table 1). A total
of six analogues were potent inhibitors of TgENR with IC50 values of less than 23 nM,
similar to that of triclosan (15 nM). None of the compounds with 2'-substitutions proved to
have significant inhibitory activity. This result is consistent with a lack of potent activity
against PfENR.43 Based on the current crystal structures of TgENR and PfENR bound to
triclosan,51 the 2'-triclosan analogues are unlikely to be effective since added bulk at this
position will likely result in severe steric clashes with the NAD+ cofactor (see docking
results for further details). Potent inhibitors of TgENR with IC50 values in the low
nanomolar range were found with substitutions at the 4'-, 5-, and 6-positions of triclosan.
Previous medicinal chemistry efforts targeting TgENR led to the discovery of several potent
4'-triclosan and 5-triclosan analogues.37–38 The activities of 6-triclosan analogues have not
previously been described against T. gondii. However, as shown in Table 1, 6-triclosan
analogues such as 15 and 17 can be inhibitors of TgENR enzymatic activity and parasite
growth.
Thermal Shift Assay (TSA)
Our current study of 18 triclosan analogues yielded six compounds with TgENR IC50 values
in the low nanomolar range (< 23 nM). These IC50 values are similar to that of triclosan (15
nM) and approach the low nanomolar concentrations of TgENR enzyme used in our activity
assay. Because of this we could not determine which of the six compounds is the most
potent or how they compare to triclosan with currently available assays. In addition we have
14 inhibitors discovered in previous studies37–38 which also inhibit TgENR with IC50 values
lower than 100 nM, making 20 compounds in total. In an attempt to differentiate between
these inhibitors, we adapted a thermal shift assay (TSA)44–46 to further characterize the
binding of the compounds to TgENR.
A significant advantage of TSA over several other biophysical techniques, such as NMR,
mass spectrometry or calorimetry, is that it can be done with higher throughput without
requiring large amounts of protein.44–46, 48, 53–55 This method has been previously
employed for screening conditions which stabilize proteins;46, 56–57 Kd calculations for
proteins with one or two ligands;44–45, 48, 55 as well as to determine the mode of action of
ligand binding.55 Calculations of Kd values by TSA have been favorably compared to
measurements done by other biophysical techniques.44
We used the TSA to measure the melting temperature (Tm) of TgENR alone, in binary
complex with NADH or NAD+ cofactor, or in a ternary complex with triclosan (or
analogues) and NADH or NAD+ bound. Using a real time PCR machine to accurately
control the temperature, we monitored the thermal denaturation of TgENR in the presence of
the environmentally sensitive dye Sypro Orange. The TSA method consists of monitoring
the fluorescence of the dye which has a higher quantum yield when it interacts with
hydrophobic amino acids exposed upon TgENR unfolding. As shown in Figure 1, the
derivative of the fluorescence intensity is marked by a sharp minimum at the Tm. A shift in
thermal stability occurs upon formation of a ligand complex and the magnitude of the shift
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in Tm depends on the affinity of the ligand for TgENR. The observed change in Tm (ΔTm =
Tm (ligand) – To (no ligand)) is used to calculate the binding constant (Kd) of the
ligand.44, 46 TSA can be particularly useful for proteins such as TgENR which have multiple
ligand binding sites and can bind inhibitors and cofactor molecules. In cases like this, the
relative stability of the protein with different combinations of ligands can be used to
determine the mode of action of an inhibitor.55
TgENR binary complex with NADH or NAD+
We studied the ΔTm of TgENR with increasing concentrations of NADH or NAD+ (Figure
2A). Each data point with a nonzero ΔTm allowed us to calculate independent Kd values for
these ligands. For NADH, Kd values of 26 µM (ΔTm = 0.4 C) and 21 µM (ΔTm = 1.7 C)
were measured, and for NAD+ the Kd values were 6 mM (ΔTm = 0.4 C) and 6 mM (ΔTm =
1.6 C). The Kd values resulting from the larger temperature shifts are likely to be the most
accurate (21 µM for NADH and 6 mM for NAD+). The Kd for NADH binding to TgENR is
similar to the value obtained for PfENR with a Kd for NADH of 51.6 µM58 and that of E.
coli ENR with a Kd for NADH of 5.4 µM.32 The Kd for NAD+ could not be determined for
PfENR, except in the presence of triclosan, yielding an artificially low value of 15 µM58 ,
whereas the Kd of NAD+ for EcENR was determined to be 1.8 mM.32 The kinetic
parameters for TgENR were calculated by using the enzymatic activity assay at 11 different
concentrations of NADH and Crotonyl-CoA in triplicate, with the highest concentration of
500 µM and dilutions by factors of two for NADH and 0.8–150 µM for Crotonyl-CoA.
Figure 2B shows a Michaelis-Menten plot for TgENR with a kcat of 12 s−1 and Km of 20 µM
for NADH; for Crotonyl-CoA, kcat is 26 s−1 and Km is 40 µM (Figure 2C). These values are
similar to those of ENR enzymes from the apicomplexan parasites Eimeria tenella and
Plasmodium falciparum (Table 2).25, 59–60 Although Km values cannot be equated with
dissociation constants, the Km values for NADH are consistent with the 21 µM Kd value
determined by TSA.
Inhibitor mode of action determined by TSA
The mode of action of ENR inhibition by triclosan has been well studied in several systems,
including apicomplexan parasites, plants and bacteria. Triclosan is an uncompetitive
inhibitor with respect to NAD+ and forms a tight ternary triclosan/NAD+/ENR complex.
Consistent with this mechanism of action, we observed a large shift in Tm when TgENR was
analyzed by TSA in the presence of triclosan and NAD+, but not in the absence of the
cofactor (Figure 1A). Interestingly, we also observed a small shift in Tm when triclosan was
added to TgENR in the presence of NADH (Figure 1A). Triclosan has an apparent Kd value
of 186 µM for the TgENR/NADH complex, an affinity that is probably too weak to have
physiological significance since this value is 100,000 times larger than the Kd of triclosan
binding to the TgENR/NAD+ complex (1.3 nM at 100 µM NAD+ listed in Table 3). The
apparent weak binding of triclosan to the TgENR/NADH complex is consistent with reports
of ternary triclosan/NADH complexes formed by ENR enzymes from E. coli,61
Haemophilus influenza62 and Pseudomonas aeruginosa.63
Potent inhibition of ENR enzymes with triclosan is due to the slow formation of a tight
ternary triclosan/NAD+/ENR complex. PfENR is 50% identical to TgENR and serves as a
good example of this phenomenon. Triclosan binds to the PfENR/NAD+ complex with
relatively low affinity (53 nM) followed by the slow (0.055 s−1 forward rate constant)
formation of a tight binding complex with an overall inhibition constant of 96 pM.64 The
tight binding complex involves the formation of an α-helix over the inhibitor binding site, a
feature that was observed in the crystal structure of TgENR co-crystallized with triclosan
and NAD+, making it very likely that triclosan inhibits TgENR through the same mechanism
as described for other ENR enzymes.51 The slow kinetics of inhibition appear to be
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responsible for the artificially high 15 nM IC50 value of triclosan shown in Table 1. The
IC50 value approaches the theoretical limit (half of the 5 nM TgENR concentration) when
the enzyme is preincubated with triclosan and NAD+ allowing the inhibitory complex to
form prior to initiating the assay. In the TSA experiments, there is a total incubation time of
about 30 minutes from the time the experiment is set up to the time it reaches Tm. This
allows enough time for triclosan to form the tight ternary complex. To confirm this, we set
up TSA experiments as explained in the Methods section, but allowed 2 hours of pre-
incubation. This pre-incubation time did not affect the Kd of triclosan for the enzyme (data
not shown). To determine the reproducibility of the TSA measurements, we measured the
Tm in four experiments in triplicates on different days for TgENR alone, in binary complex
with NADH and NAD+ and in the ternary complex TgENR/NAD+/triclosan. The standard
deviation of these measurements was 0.40, 0.56, 0.36 and 0.37 degree Celsius, respectively.
All of our potent inhibitors were also tested by TSA for binding to the TgENR/NAD+
complex, the TgENR/NADH complex, or TgENR alone. In all cases, the inhibitors
displayed a similar mode of action as that of triclosan, forming a tight complex with
TgENR/NAD+. Figure 1B shows the TSA results for 32, a compound that differs
significantly from the structure of triclosan, but displays a similar Tm shift profile and thus
the same mode of action as triclosan, binding exclusively to the TgENR/NAD+ complex. As
shown in Figure 1, the presence of 100 µM NAD+ alone (orange curves) or 20 µM inhibitor
alone (green curves) does not shift the Tm of TgENR and thus, the ΔTm observed in the
presence of inhibitor and NAD+ is due to the formation of the ternary complex.
Effect of NAD+ concentration on inhibitor affinity
In TSA experiments we can control the concentration of the cofactors NADH and NAD+.
By contrast, in the enzymatic assay NADH is constantly being consumed and NAD+ is
formed over the course of the reaction. For TSA, we used 100 µM NADH, the concentration
used as the starting point in the enzymatic assay. As described above, this concentration is
well above the 21 µKd of NADH, ensuring that the majority of TgENR forms a binary
TgENR/NADH complex during the TSA experiments. The same is not true for NAD+. In
the TSA experiments described above, 100 µM NAD+ was used whereas the Kd is 6 mM.
Under these conditions, the fraction of enzyme found as a binary TgENR/NAD+ complex is
very small (~1.6%).
We then analyzed the binding of two inhibitors, triclosan and 32, to better understand how
NAD+ concentration affects the apparent Kd values determined by TSA. We determined Kd
values for both inhibitors at eight concentrations of NAD+ ranging from 2.7 µM to 6 mM.
As shown in Figure 3A, the apparent Kd for these inhibitors decreases as the concentration
of NAD+ increases, until reaching a plateau while approaching the Kd of NAD+ (6 mM).
The apparent dissociation constant of triclosan ranges from 18 µM (at a NAD+ concentration
of 2.7 µM) to 20 fM (at a NAD+ concentration of 6 mM), despite the fact that NAD+ is in
stoichiometric excess to TgENR (2 µM) throughout this concentration range. Similarly, the
Kd values for compound 32 vary from 51 µM to 689 fM over the same range of NAD+
concentrations. These results underscore the need to consider cofactor concentration when
comparing Kd values for uncompetitive inhibitors like triclosan. For example, a Kd value of
32 nM was reported for triclosan binding to PfENR58 which is similar to the value of 1.3 nM
listed in Table 3 for TgENR. However, the Kd for PfENR was determined with 250 µM
NAD+ and the equivalent Kd value for TgENR is 105 pM. In a similar experiment, we
determined the Kd values for triclosan and compound 32 at seven concentrations ranging
from 450 nM to 333 µM, while keeping [NAD+] constant at 100 µM. As expected, we found
that the Kd values for both compounds decrease as we increase the inhibitor concentration
(Figure 3B).
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We determined the Kd values for our most potent TgENR inhibitors in the presence of 6 mM
NAD+ and compared these values with those determined at 100 µM NAD+ (Table 3). The
higher NAD+ concentration increased the apparent affinity of all of our inhibitors, however,
the factor by which the affinity increased was not uniform across the compound series
(Table 3). The Kd of 25 decreased by a factor of 2,300,000 when NAD+ concentrations were
increased, whereas the Kd of 30 only decreased by a factor of 11,000. Even between similar
compounds such as 28 and 29 there were differences in the dependence of Kd on NAD+
concentrations. These differences may reflect the ability of some inhibitors to bind more
tightly to TgENR in the absence of NAD+. In the thermodynamic cycle shown in Figure 4A,
these inhibitors would have smaller Ki values and larger α values corresponding to less
selectivity between binding to the TgENR/NAD+ complex versus TgENR alone.
We did not detect the binding of any inhibitor to TgENR when we used 20 µM inhibitor
concentrations, however, Ki values could be well above this level. We screened for inhibitor
binding at higher concentrations of inhibitor (111 µM and 333 µM) but found that most
compounds did not have measureable binding or interfered with the TSA at these
concentrations. Compound 29, however, appeared to bind with a dissociation constant (Ki)
of 0.8 mM (Figure 4B). This value of Ki allows us to estimate the parameter α if we can
measure the affinity of compound 29 for the E•NAD complex (αKi) shown in Figure 4A.
The Kd of compound 29 in the presence of 6 mM NAD+ is 116 pM (Table 3). We can
estimate αKi using the equation for the binding of uncompetitive inhibitors
in which  is the observed dissociation constant of the inhibitor at any concentration of
NAD+ and KNAD is the Kd of NAD+. Since the 6 mM concentration of NAD+ used in the
TSA equals KNAD, this equation reduces to:
Similar estimations of αKi can be made for all of the compounds with measured Kd values
at 6 mM NAD+ (Table 3). The parameter α describing the selectivity of compound 29 for
the binary complex would then be 7×10−8. The parameter α is presumably related to the
ratio of Kd values shown in Table 3 in the sense that both numbers provide an indication of
how dependent an inhibitor is on binding to the binary TgENR/NAD+ complex. This
phenomenon may help to guide the selection of the best inhibitors. The NAD+ concentration
has been measured in different cell types, including mouse erythrocytes and mammalian
cells with values of 368 µM and a range of 300–800 µM, respectively.65–69 Although the
concentration of NAD+ in the apicoplast of T. gondii has not been measured, it is also likely
to be well below the 6 mM Kd value. Therefore, at any given time, most TgENR molecules
will not have NAD+ bound. Indeed, the large discrepancy between the MIC50 values in
Table 1 and the extremely tight binding properties of some of the compounds in Table 3
may be an indication that NAD+ levels are low in the apicoplast organelle.
Inhibitor affinity to the TgENR/NAD+ complex
The twenty compounds that we examined by TSA all had IC50 values of less than 100 nM in
the TgENR enzyme activity assay (Table 3). The calculated Kd values at the two NAD+
concentrations can be used to identify the most potent compounds and how dependent
inhibitor binding is on NAD+ concentration (Table 3). A total of six compounds showed Kd
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values of less than 10 nM with 100 µM NAD+, and less than 100 fM with 6 mM NAD+ (5,
9, 10, 15, 19 and 27). From analyzing these compounds, it is clear that tight binding
inhibitors can contain small substituents at the 4'-position (as in compound 5), the 5-position
(as in compound 19), or the 6-position (as in compound 15). As described previously37–38 ,
bulky substituents at the 4'- and 5-positions are accommodated by the TgENR active site.
Compound 27 contains a large isoxazole ring at the 5-position while compounds 9 and 10
contain a benzylamino moiety. The 6-position triclosan analogues have not been described
previously for TgENR. We show that modifications at this position are well tolerated as seen
for compounds 15 and 17 (see modeling data below).
Overall, three compounds (5, 9 and 19) appear to bind to the TgENR/NAD+ complex as well
as triclosan or better. These compounds differ, however, in terms of how dependent the
dissociation constants are on NAD+ concentration. The ratio of Kd values determined at low
and high NAD+ concentrations is 250,000 for compound 19, whereas this ratio is only
30,000 for compound 9 (Table 3). As discussed above, the reduced dependence of
compound 9 on NAD+ concentration could reflect the ability of this compound to bind
weakly to TgENR, adding an additional route to forming the ternary inhibitor/TgENR/NAD+
complex. By contrast, compound 19 may be more dependent on binding to a preformed
TgENR/NAD+ complex. In this sense, compound 9 could prove to be a more exciting
scaffold for further modification. Since a variety of substituents are tolerated at the 5-
position, these are possible additions that could improve the properties of compound 9.
Similarly, small groups such as those found in compounds 15 and 17 could be added to the
6-position.
Inhibitor Modeling
In order to further understand the different binding properties of the various inhibitors
studied, molecular modeling was carried out using the TgENR crystal structure and the
molecular docking software AutoDock.49 The least effective triclosan analogues contained
modifications on the B-ring at the 2'-position. The close proximity of the NAD+ cofactor to
this position on the B-ring is likely to cause a significant steric clash upon inhibitor binding
(Figure 5A). The addition of a 5-methyl-3-carboxamide-isoxazole group to the A- or B-rings
of triclosan resulted in a marked difference in their Kd values. The presence of this group at
the 5-position on the A-ring (compound 27) produced a very potent inhibitor (Kd = 33 fM
with 6 mM NAD+), whereas this modification at the 4'-position on the B-ring gave inhibitor
29 with 3,500 fold less affinity (Kd = 116 pM with 6 mM NAD+).
Molecular modeling was used to rationalize this difference in affinity. Modeling in
AutoDock suggested that the isoxazole group, and other large substituents37–38 can be
tolerated within the hydrophobic pocket surrounding the A-ring due to the mobile alpha
helix. Conversely, the positioning of this group on the B-ring extends towards the solvent
exposed entrance to the binding site, and should be able to accommodate such a substituent.
However, sampling the potential ligand conformations in AutoDock exposed a steric clash
between the 4'-methylisoxazole of compound 29 and Phe243 (TgENR numbering) due to the
rigid nature of the 5-methyl-3-carboxamide-isoxazole group. The addition of a methylene
group between the amide and isoxazole ring (compound 28) decreased the Kd by about two
orders of magnitude, perhaps because the additional flexibility alleviated this steric clash.
The most promising inhibitors discovered to date have a modification at the 6-position on
the A-ring. Considering the extra bulk of the nitrile (compound 15) and the hydroxymethyl
(compound 17) moieties, the initial steric clash observed between these substituents and
Tyr179 must be alleviated through the movement about Cβ. This result is corroborated
through further modeling studies whereby the conserved Tyr179 residue can rotate to
accommodate the 6-substitutents within the heart of the binding site (Figure 5B).
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CONCLUSIONS
We evaluated a series of triclosan analogues as inhibitors of Toxoplasma gondii. The 4'- and
5-substituted triclosan analogues are effective inhibitors of parasite growth and TgENR
enzymatic activity. Compounds with modifications at the 2'-position did not show inhibitory
activity against TgENR due to steric clashes with either the NAD+ cofactor or the top of the
binding pocket. Modifications in the 6-position were well tolerated and displayed good
inhibitory activity against the parasite and the TgENR enzyme. Six compounds which
inhibited TgENR with IC50 values in the low nanomolar range were identified, but could not
be further differentiated due to the limited dynamic range of the TgENR activity assay. A
thermal shift assay was employed to further characterize these compounds as well as 14
other potent inhibitors from previous studies.37–38 All 20 compounds share the same mode
of action and form a ternary complex with TgENR and NAD+, but do not bind significantly
to the TgENR/NADH complex or to TgENR alone. The apparent Kd values for the inhibitors
were strongly affected by NAD+ concentration and reached a plateau as the NAD+
concentration approached the 6 mM Kd of NAD+. By comparing the apparent Kd values of
the inhibitors at low and high NAD+ concentrations, we could identify potent compounds
which are less dependent on NAD+ binding. Ultimately, we were able to identify six
compounds which bind to the TgENR/NAD+ complex in the low femtomolar range with
affinities similar to or exceeding that of triclosan (5, 9, 10, 15, 19 and 27). Additionally, four
of these compounds inhibit the growth of T. gondii parasites with equal or better potency
than triclosan (5, 9, 10 and 15). TSA data combined with enzyme inhibition and parasite
growth inhibition data allow for better discrimination between potent ENR inhibitors, and
therefore provide an excellent method for better selection of promising lead compounds.
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ACP acyl carrier protein
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Figure 1.
Thermal Shift Assay results for triclosan (red curves) and compound 32 (blue curves). The
derivatives of the fluorescence intensity curves are shown with the minima defining the
melting temperatures (Tm). Enzyme alone – green; Enzyme/NADH – black; Enzyme/NAD+
- orange.
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Figure 2.
A) Thermal Shift Assay results for the binding of NADH (red) and NAD+ (blue) to TgENR.
B) Kinetic analysis of TgENR with NADH cofactor. C) Kinetic analysis of TgENR with
Crotonyl-CoA cofactor. Error bars represent the standard deviation from triplicate
measurements.
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Figure 3.
Effect of NAD+ and inhibitor concentration on the apparent dissociation constant of two
TgENR inhibitors. Thermal Shift Assay was used to determine apparent Kd values for
triclosan (red) and compound 32 (blue) at different concentrations of NAD+ and inhibitor.
A) The apparent dissociation constants reach a plateau as NAD+ concentrations approach 6
mM (the Kd of NAD+). B) The apparent dissociation constants decrease as the inhibitor
concentration increases to 333 µM, the highest concentration we were able to measure. Error
bars represent the standard deviation of triplicate measurements.
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Figure 4.
Thermodynamic cycle for formation of the ternary inhibitor/TgENR/NAD+ complex. The
parameter α describes the selectivity of inhibitor binding for the TgENR/NAD+ complex
(E•NAD) and the selectivity of NAD+ binding to the inhibitor/TgENR complex (E•I).
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Figure 5.
A) The NAD+/triclosan binding pocket of TgENR from a crystal structure (PDB ID: 202S)51
Ligands NAD+ and triclosan are shown in stick format colored by atom type. Modification
of the 2' atom (marked with an asterisk) results in decreased affinity (see compounds 1, 2, 3
and 4) due to steric clashes with the NAD+ cofactor and the binding pocket. B) Molecular
modeling of inhibitor 17 showing the position of the additional OH group and its close
proximity to the two fully conserved active site Tyr residues.
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